Role of lecithin-cholesterol acyltransferase in the metabolism of oxidized phospholipids in plasma: studies with platelet-activating factor-acetyl hydrolase-deficient plasma.
To determine the relative importance of platelet-activating factor-acetylhydrolase (PAF-AH) and lecithin-cholesterol acyltransferase (LCAT) in the hydrolysis of oxidized phosphatidylcholines (OXPCs) to lyso-phosphatidylcholine (lyso-PC), we studied the formation and metabolism of OXPCs in the plasma of normal and PAF-AH-deficient subjects. Whereas the loss of PC following oxidation was similar in the deficient and normal plasmas, the formation of lyso-PC was significantly lower, and the accumulation of OXPC was higher in the deficient plasma. Isolated LDL from the PAF-AH-deficient subjects was more susceptible to oxidation, and stimulated adhesion molecule synthesis in endothelial cells, more than the normal LDL. Oxidation of 16:0-[1-14C]-18:2 PC, equilibrated with plasma PC, resulted in the accumulation of labeled short- and long-chain OXPCs, in addition to the labeled aqueous products. The formation of the aqueous products decreased by 80%, and the accumulation of short-chain OXPC increased by 110% in the deficient plasma, compared to the normal plasma, showing that PAF-AH is predominantly involved in the hydrolysis of the truncated OXPCs. Labeled sn-2-acyl group from the long-chain OXPC was not only hydrolyzed to free fatty acid, but was preferentially transferred to diacylglycerol, in both the normal and deficient plasmas. In contrast, the acyl group from unoxidized PC was transferred only to cholesterol, showing that the specificity of LCAT is altered by OXPC. It is concluded that, while PAF-AH carries out the hydrolysis of mainly truncated OXPCs, LCAT hydrolyzes and transesterifies the long-chain OXPCs.
Departments of Medicine and Biochemistry, Rush Medical College, 1653 West Congress Parkway, Chicago, IL 60612, USA.
V S
VS
Subramanian
J
J
Goyal
M
M
Miwa
J
J
Sugatami
M
M
Akiyama
M
M
Liu
P V
PV
Subbaiah
D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase; D043303:Aryldialkylphosphatase; D004075:Diglycerides / Q000378:metabolism; D004950:Esterases / Q000378:metabolism; D006801:Humans; D007531:Isoflurophate / Q000494:pharmacology; D008077:Lipoproteins, LDL / Q000302:isolation & purification / Q000378:metabolism; D008244:Lysophosphatidylcholines / Q000378:metabolism; D010084:Oxidation-Reduction; D007862:Phosphatidylcholine-Sterol O-Acyltransferase / Q000378:metabolism*; D010713:Phosphatidylcholines / Q000097:blood / Q000378:metabolism; D010741:Phospholipases A / Q000172:deficiency*; D010743:Phospholipids / Q000097:blood / Q000378:metabolism*; D010972:Platelet Activating Factor / Q000378:metabolism*; D013450:Sulfones / Q000494:pharmacology
D004075:Diglycerides; D008077:Lipoproteins, LDL; D008244:Lysophosphatidylcholines; D010713:Phosphatidylcholines; D010743:Phospholipids; D010972:Platelet Activating Factor; D013450:Sulfones; D007531:Isoflurophate; C002010:4-(2-aminoethyl)benzenesulfonylfluoride; D007862:Phosphatidylcholine-Sterol O-Acyltransferase; D004950:Esterases; D010741:Phospholipases A; D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase; D043303:Aryldialkylphosphatase